Psilocybin Therapy for Alcohol Use Disorder: Evidence Review and Policy Implications

Current Evidence: No Clear Efficacy for Psilocybin in Alcohol Use Disorder

The latest systematic review of randomized controlled trials (RCTs), published on November 6, 2026 (OpenAlex W7225401931), finds that psilocybin-assisted therapy does not have established efficacy for alcohol use disorder (AUD). The review synthesizes data from three RCTs (total n=165) and concludes that all outcomes were at high risk of bias, with low or very low certainty of evidence for both reduction in heavy-drinking days and abstinence. While some individual trials reported reduced heavy-drinking days or improved short-term abstinence, these findings were inconsistent and highly sensitive to methodological limitations, such as small sample sizes and functional unblinding.

Mechanisms, Methodological Weaknesses, and Context

Psilocybin, a serotonergic psychedelic, has been hypothesized to facilitate psychological change through neuroplasticity and enhanced therapeutic engagement, potentially addressing the underlying behavioral and emotional drivers of AUD. However, the reviewed trials were hampered by several methodological issues. All studies relied heavily on self-reported alcohol use, which is particularly vulnerable to bias in unblinded or partially blinded settings. One trial reported fewer heavy-drinking days with psilocybin versus active placebo, but another found no significant differences in alcohol consumption, abstinence, or relapse at either 4 weeks or 6 months. A small feasibility study noted higher abstinence rates at 12 weeks with a 25-mg dose, but this result was based on a handful of participants and was sensitive to missing data assumptions.

Importantly, the review highlights a non-obvious failure mode: functional unblinding—where participants and therapists correctly guess treatment assignment due to the perceptible effects of psilocybin—can undermine the reliability of self-reported outcomes, especially in behavioral health trials. This issue is rarely addressed in other addiction studies and complicates interpretation of efficacy signals.

Policy and Research Implications

Regulators, policymakers, and funders should note that the current evidence base does not support psilocybin-assisted therapy as a validated treatment for AUD. The U.S. Food and Drug Administration (FDA) and similar agencies in Canada, the United Kingdom, and Australia have not approved psilocybin for any substance use disorder indication. The review underscores the necessity of larger, multi-site RCTs with robust blinding, objective endpoints (such as biochemical verification of alcohol use), standardized therapeutic protocols, and longer follow-up periods to assess durability of effects. These design features are critical for future trials to generate credible efficacy and safety data that could inform regulatory or clinical guidelines.

For researchers, the review signals a need to move beyond small, single-site studies and to address functional unblinding directly, perhaps by using active placebos with more comparable subjective effects or by incorporating digital biomarkers and collateral reports to supplement self-report measures.

Risks, Unknowns, and Safety Profile

Psilocybin administration in the reviewed trials was generally well-tolerated, with adverse effects described as transient and no deaths reported. However, the small sample sizes and short follow-up periods preclude robust conclusions about rare or delayed adverse events, including potential for psychological distress, misuse, or exacerbation of psychiatric symptoms. The low certainty of evidence also means that potential harms, such as increased relapse risk or negative interactions with concurrent medications, remain insufficiently characterized. Policymakers and clinicians should exercise caution and avoid premature adoption of psilocybin therapy for AUD outside of well-controlled research settings.

Looking Forward: Research Priorities and Regulatory Caution

The field of psychedelic-assisted therapy for addiction is at an inflection point, with public and commercial interest running ahead of the scientific evidence. This systematic review serves as a cautionary signal: enthusiasm should be tempered by the recognition that current RCT data do not establish efficacy for psilocybin in treating alcohol use disorder. The next generation of trials must address methodological weaknesses—especially functional unblinding and reliance on self-report—and prioritize objective, durable outcomes. Until such data are available, regulatory and clinical adoption should remain highly circumspect.

By Dr. Alex J. Morgan, PhD (Neuroscience, Policy Editor)How we research: This analysis is based on direct review of the systematic review published in OpenAlex (W7225401931), cross-referenced with FDA guidance and trial registry data. Reviewed by Dr. Alex J. Morgan on 2026-11-08.